CA2884757A1 - Anti-pain and anti-nausea and/or vomiting combinatorial compositions - Google Patents

Anti-pain and anti-nausea and/or vomiting combinatorial compositions Download PDF

Info

Publication number
CA2884757A1
CA2884757A1 CA2884757A CA2884757A CA2884757A1 CA 2884757 A1 CA2884757 A1 CA 2884757A1 CA 2884757 A CA2884757 A CA 2884757A CA 2884757 A CA2884757 A CA 2884757A CA 2884757 A1 CA2884757 A1 CA 2884757A1
Authority
CA
Canada
Prior art keywords
film
drug delivery
delivery system
active component
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2884757A
Other languages
English (en)
French (fr)
Inventor
Eric Dadey
Garry Myers
Daniel Barber
Mark Schobel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aquestive Therapeutics Inc
Original Assignee
MonoSol Rx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MonoSol Rx LLC filed Critical MonoSol Rx LLC
Publication of CA2884757A1 publication Critical patent/CA2884757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2884757A 2012-09-12 2013-09-12 Anti-pain and anti-nausea and/or vomiting combinatorial compositions Abandoned CA2884757A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261700146P 2012-09-12 2012-09-12
US61/700,146 2012-09-12
US13/843,718 US20140073678A1 (en) 2012-09-12 2013-03-15 Anti-pain and anti-nausea and/or vomiting combinatorial compositions
US13/843,718 2013-03-15
PCT/US2013/059460 WO2014043346A2 (en) 2012-09-12 2013-09-12 Anti-pain and anti-nausea and/or vomiting combinatorial compositions

Publications (1)

Publication Number Publication Date
CA2884757A1 true CA2884757A1 (en) 2014-03-20

Family

ID=50233885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2884757A Abandoned CA2884757A1 (en) 2012-09-12 2013-09-12 Anti-pain and anti-nausea and/or vomiting combinatorial compositions

Country Status (6)

Country Link
US (1) US20140073678A1 (https=)
EP (1) EP2895145A2 (https=)
JP (1) JP2015528504A (https=)
AU (1) AU2013315484A1 (https=)
CA (1) CA2884757A1 (https=)
WO (1) WO2014043346A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US20140275194A1 (en) * 2013-03-15 2014-09-18 Monosol Rx, Llc Films and drug delivery systems for rizatriptan
NZ727834A (en) 2014-06-24 2020-08-28 Taho Pharmaceuticals Ltd Fast acting orally disintegrating film
CA2960116A1 (en) * 2014-09-09 2016-03-17 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
IL270654B2 (en) 2017-05-17 2024-07-01 Confluence Pharmaceuticals Llc Formulations of homotaurines and salts thereof
EP3691610A1 (en) * 2017-10-07 2020-08-12 Zim Laboratories Limited Process for the preparation of bi/multi-layer film, multi-layered film produced thereof and apparatus for producing such multi-layer films
DE102017127452A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag Wasserlösliche Polymerklebschichten
US20240003872A1 (en) * 2020-11-15 2024-01-04 Aphios Corporation Methods for assaying and measuring the efficacy of anti-nausea compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2392810A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
JP2008534562A (ja) * 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット 偏頭痛の治療に有用な新しい製薬組成物
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN105168186A (zh) * 2006-10-02 2015-12-23 Apr应用制药研究股份公司 非粘膜粘着性膜剂型
AU2009241847B2 (en) * 2008-04-28 2014-07-10 Zogenix, Inc. Novel formulations for treatment of migraine
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
PT2952191T (pt) * 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
WO2011006012A1 (en) * 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
CN102028672B (zh) * 2010-09-29 2012-08-29 上海现代药物制剂工程研究中心有限公司 微孔海绵状药膜制剂及其制备方法

Also Published As

Publication number Publication date
JP2015528504A (ja) 2015-09-28
US20140073678A1 (en) 2014-03-13
AU2013315484A1 (en) 2015-04-09
WO2014043346A3 (en) 2014-07-31
WO2014043346A2 (en) 2014-03-20
EP2895145A2 (en) 2015-07-22

Similar Documents

Publication Publication Date Title
US20140073678A1 (en) Anti-pain and anti-nausea and/or vomiting combinatorial compositions
US20230138361A1 (en) Enhanced delivery epinephrine compositions
US8840919B2 (en) Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
ES2355439T3 (es) Parche bioerosionable.
JP2023134518A (ja) 透過性増強された医薬組成物
JP5717946B2 (ja) ポリビニルアルコール−ポリエチレングリコールグラフト共重合体を含有する泡状ウェハ
JP2019048882A (ja) 舌下及び頬用フィルム組成物
BR112013015204A2 (pt) composição farmacêutica em forma de unidade de dosagem formulada para administração sublingual e uso da referida composição
CZ20012566A3 (cs) Jednotková dávka a způsob přípravy jednotkové dávky pro slizniční podávání
CN103298459A (zh) 用于直接在包装表面上形成药用产品的方法和系统
JP2009518405A (ja) 活性物質の送達のための局所フィルム組成物
JP2010265319A (ja) 粘膜表面への、薬剤化合物の送達に適する薬剤キャリアデバイス
CA2621263A1 (en) Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
CN107519150A (zh) 置入口腔的剂型
JP2026027254A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物
JP2017537127A (ja) 線状多糖をベースとするフィルム製品
JPS58213709A (ja) 歯肉粘膜用貼付剤
EP4058029B1 (en) Multimodal compositions and methods of treatment
Chauhan et al. A comprehensive review on mucoadhesive drug delivery
JP2009521532A (ja) 活性物質を放出するための、ｐＨ調節されたフィルム
EP2889030A1 (en) Controlling the erosion rates of mucoadhesive devices that deliver actives and other compounds and providing increased and variable therapeutic blood levels
JP2024543149A (ja) 経口マイクロニードルパッチ
Gosavi et al. Mouth dissolving films: A review
Sinha et al. Oral soluble films: attributes of the polymeric material and critical process parameters for designing good quality films
CA2906050C (en) Films and drug delivery systems for rizatriptan

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160914